Scarica l'app Stockscreener
0.601
1.64%
-0.01
Precedente Chiudi:
$0.611
Aprire:
$0.61
Volume 24 ore:
37,139
Relative Volume:
0.33
Capitalizzazione di mercato:
$13.63M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.9246
EPS:
-0.65
Flusso di cassa netto:
$-22.29M
1 W Prestazione:
+10.09%
1M Prestazione:
+5.62%
6M Prestazione:
-31.20%
1 anno Prestazione:
-82.83%
Intervallo 1D:
$0.5807
$0.6173
Intervallo di 1 settimana:
$0.5201
$0.6331
Portata 52W:
$0.477
$4.99
BiomX Inc Stock (PHGE) Company Profile
Nome
BiomX Inc
Settore
Industria
Telefono
972 7 23942377
Indirizzo
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Confronta PHGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.601 | 13.63M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-15 | Iniziato | Ladenburg Thalmann | Buy |
BiomX Inc Borsa (PHGE) Ultime notizie
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 48.2% - Defense World
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
BiomX’s $12 Million Financing - Global Legal Chronicle
BiomX Inc. secures $12 million from recent offerings - Investing.com India
Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan
BiomX Inc Azioni (PHGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):